CALGB 10403 outcomes of interest, stratified by race/ethnicity
| . | NHW (n = 172) . | Hispanic (n = 45) . | NHB (n = 25) . | P . |
|---|---|---|---|---|
| Days on treatment | .39 | |||
| Median | 469 | 786.5 | 224 | |
| IQR | 89.5-990 | 107-1200 | 104-872 | |
| Protocol completion | .055 | |||
| Nonadherence, no. (%) | 76 (44) | 11 (24) | 9 (36) | |
| 100-day mortality, no. (%) | 4 (2) | 2 (4) | 2 (8) | .18 |
| 3-year EFS (95% CI) | 60% (53-68) | 55% (41-72) | 42% (26-67) | .30 |
| 3-year OS (95% CI) | 74% (67-81) | 75% (63-90) | 58% (41-82) | .17 |
| . | NHW (n = 172) . | Hispanic (n = 45) . | NHB (n = 25) . | P . |
|---|---|---|---|---|
| Days on treatment | .39 | |||
| Median | 469 | 786.5 | 224 | |
| IQR | 89.5-990 | 107-1200 | 104-872 | |
| Protocol completion | .055 | |||
| Nonadherence, no. (%) | 76 (44) | 11 (24) | 9 (36) | |
| 100-day mortality, no. (%) | 4 (2) | 2 (4) | 2 (8) | .18 |
| 3-year EFS (95% CI) | 60% (53-68) | 55% (41-72) | 42% (26-67) | .30 |
| 3-year OS (95% CI) | 74% (67-81) | 75% (63-90) | 58% (41-82) | .17 |
CI, confidence interval; EFS, event-free survival; IQR, interquartile range; No., number.